Zoe Johnson

Employment

• Affivant CSO
  2022 - Present
• iOnctura SA CSO
  2017 - 2022
• NovImmune SA
  2013 - 2016
• Merck Serono
  2008 - 2013
• UCB Celltech
  2004 - 2008

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (92)

• Supplementary Table S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.22505455
  +Save
• Table S2 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
  2023 DOI: 10.1158/2767-9764.22546784
  +Save
• Table S2 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
  2023 DOI: 10.1158/2767-9764.22546784.v1
  +Save
• Table S3 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
  2023 DOI: 10.1158/2767-9764.22546781.v1
  +Save
• Table S3 from IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that targets solid tumors and breaks immune tolerance
  2023 DOI: 10.1158/2767-9764.22546781
  +Save
• Data from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.c.6538060.v1
  +Save
• Data from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.c.6538060
  +Save
• Supplementary Figure S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.22505464.v1
  +Save
• Supplementary Figure S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.22505464
  +Save
• Supplementary Figure S2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
  2023 DOI: 10.1158/1535-7163.22505461.v1
  +Save